Over the last 7 days, the Life Sciences industry has dropped 4.3%, driven by declines in WuXi Biologics (Cayman) and WuXi XDC Cayman of 3.5% and 6.8%, respectively. Meanwhile, Zhejiang Taimei Medical Technology actually outperformed within the industry, gaining 9.6% in the last week. Over the past 12 months, the industry was up 47%. As for the next few years, earnings are expected to grow by 32% per annum.
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Wed, 14 May 2025 | HK$187.5b | HK$35.9b | HK$2.6b | 25.9x | 72.6x | 5.2x |
Fri, 11 Apr 2025 | HK$163.6b | HK$35.2b | HK$2.5b | 24.4x | 65x | 4.6x |
Sun, 09 Mar 2025 | HK$200.0b | HK$35.9b | -HK$1,056,224,592.40 | 44.4x | -189.3x | 5.6x |
Tue, 04 Feb 2025 | HK$156.2b | HK$36.0b | -HK$1,059,833,639.34 | 52.6x | -147.4x | 4.3x |
Thu, 02 Jan 2025 | HK$158.6b | HK$35.7b | -HK$1,058,290,871.23 | 58x | -149.9x | 4.4x |
Sat, 30 Nov 2024 | HK$136.7b | HK$35.9b | -HK$1,058,204,562.01 | 51.7x | -129.1x | 3.8x |
Mon, 28 Oct 2024 | HK$163.9b | HK$35.7b | -HK$659,995,106.50 | 31.6x | -248.4x | 4.6x |
Wed, 25 Sep 2024 | HK$143.2b | HK$36.1b | -HK$653,046,298.07 | 26.8x | -219.2x | 4x |
Fri, 23 Aug 2024 | HK$94.3b | HK$35.9b | HK$2.0b | 16.6x | 47.1x | 2.6x |
Sun, 21 Jul 2024 | HK$93.2b | HK$33.4b | HK$3.1b | 18.4x | 30.3x | 2.8x |
Tue, 18 Jun 2024 | HK$92.3b | HK$33.5b | HK$3.1b | 23.2x | 30x | 2.8x |
Thu, 16 May 2024 | HK$111.2b | HK$33.6b | HK$3.1b | 30.7x | 35.9x | 3.3x |
Sat, 13 Apr 2024 | HK$111.9b | HK$33.6b | HK$3.1b | 32.2x | 36.1x | 3.3x |
Mon, 11 Mar 2024 | HK$133.1b | HK$32.3b | HK$3.0b | 59.6x | 44.7x | 4.1x |
Wed, 07 Feb 2024 | HK$132.2b | HK$32.6b | HK$3.0b | 52x | 43.7x | 4.1x |
Fri, 05 Jan 2024 | HK$203.8b | HK$32.4b | HK$3.0b | 90.7x | 68x | 6.3x |
Sun, 03 Dec 2023 | HK$276.7b | HK$32.4b | HK$3.0b | 94.2x | 92x | 8.5x |
Tue, 31 Oct 2023 | HK$269.7b | HK$30.1b | HK$2.7b | 48.4x | 101.3x | 9x |
Thu, 28 Sep 2023 | HK$241.3b | HK$30.1b | HK$2.7b | 42.6x | 90.5x | 8x |
Sat, 26 Aug 2023 | HK$235.8b | HK$30.3b | HK$2.7b | 23.5x | 85.9x | 7.8x |
Mon, 24 Jul 2023 | HK$221.3b | HK$28.5b | HK$2.7b | 23.4x | 81x | 7.8x |
Wed, 21 Jun 2023 | HK$210.8b | HK$28.5b | HK$2.7b | 22.5x | 76.9x | 7.4x |
Fri, 19 May 2023 | HK$235.9b | HK$29.0b | HK$2.8b | 22x | 83.3x | 8.1x |
Sun, 16 Apr 2023 | HK$284.5b | HK$29.7b | HK$3.0b | 18.4x | 94.8x | 9.6x |
Tue, 14 Mar 2023 | HK$261.1b | HK$26.4b | HK$2.1b | 23x | 126x | 9.9x |
Thu, 09 Feb 2023 | HK$336.7b | HK$26.7b | HK$2.1b | 26.7x | 157.7x | 12.6x |
Sat, 07 Jan 2023 | HK$343.6b | HK$26.4b | HK$2.1b | 28.1x | 164.7x | 13x |
Mon, 05 Dec 2022 | HK$268.9b | HK$25.8b | HK$2.0b | 26.8x | 137.8x | 10.4x |
Wed, 02 Nov 2022 | HK$210.6b | HK$25.2b | HK$1.8b | 20.1x | 118.1x | 8.3x |
Fri, 30 Sep 2022 | HK$248.0b | HK$25.5b | HK$1.8b | 20.8x | 134.1x | 9.7x |
Sun, 28 Aug 2022 | HK$373.3b | HK$25.4b | HK$2.8b | 11x | 134x | 14.7x |
Tue, 26 Jul 2022 | HK$410.5b | HK$22.3b | HK$2.0b | 12.7x | 200.7x | 18.4x |
Thu, 23 Jun 2022 | HK$361.0b | HK$22.5b | HK$2.1b | 15x | 172.8x | 16.1x |
Sat, 21 May 2022 | HK$296.6b | HK$22.4b | HK$2.1b | 13.4x | 143.1x | 13.2x |
143.1x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | 2.09% | |
Healthcare | -3.00% | |
Life Sciences | -1.62% | |
Clinical Research and Equipment | -1.62% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
1873 Viva Biotech Holdings | HK$1.60 | 7.4% +HK$228.3m | 150.0% | PE18.6x | |
1521 Frontage Holdings | HK$1.14 | 1.8% +HK$40.5m | -10.9% | PE374.2x | |
8225 China Health Group | HK$0.16 | 6.0% +HK$9.0m | 33.3% | PS5.6x |